linjc16/ctgov huggingface dataset:
The Relationship Between Adipokines, Obesity and Insulin Resistance in Women With Polycystic Ovarian Syndrome

Study Overview
=================
Brief Summary
-----------------
To evaluate possible clinical effects of adipokines , ( ghrelin, resistin and adiponectin), in obese and non-obese patients with polycystic ovary syndrome (PCOS).

Detailed Description
-----------------
Seventy selected PCOS patients will be recruited for this study, and will be divided into two groups based on their body mass index (BMI): 35 obese (BMI≥ 25 kg/m2, group A), 35 non-obese (BMI<25 kg/m2, group B). In addition, 35 healthy non-obese women (BMI<25 kg/m2) will bw enrolled as the control (group C). Serum levels of FSH (follicle stimulating hormone), LH (luteinizing hormone), T(testosterone), glucose, insulin, adiponectin, resistin and resistin will bw detected, and compared the differences of them among three groups

Official Title
-----------------
Evaluation of Adipokines ( Ghrelin, Resistin and Adiponectin), in Egyptian Women With Polycystic Ovary Syndrome

Conditions
-----------------
Polycystic Ovarian Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Females with PCOS in child bearing age who presented at reproductive and endocrinology clinics at Ain Shams University Maternity Hospital Exclusion Criteria: Known androgen secreting tumor. PCO on ovarian stimulation medications PCO with any other medical illness.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Obese PCOS<br>PCOS patients with BMI more than 25 kg/m2 | |
| Lean PCOS<br>PCOS patients with BMI less than 25 kg/m2 | |
| PCOS with normal HOMA2-1R<br>PCOS without Insuline resistance | |
| PCOS with elevated HOMA2-IR<br>PCOS with Insuline resistance | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| serum ghrelin level | measuring ghrelin, and ) in the three groups | 24 hours | 
| serum resistin level | serum resistin level in the three groups | 24 hours | 
| serum adiponectin level | serum adiponectin level in the three groups | 24 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Glucose/Insulin ratio | fasting glucose and insulin in three groups | 24 hours | 
| serum testosterone level | serum testosterone level in three groups | 24 hours after labor |
Investigation of Efficacy and Tolerability of a Lactic Acid Containing Vaginal Suppository in Post-menopausal Women With VVA

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to investigate the efficacy and tolerability of a lactic acid containing vaginal suppository with respect to the application in post-menopausal women with VVA.

Official Title
-----------------
Prospective, Open-label, Monocenter, Trial to Investigate the Efficacy and Tolerability of WO533, a Lactic Acid Containing Vaginal Suppository, in a Panel of Post-menopausal Women Suffering From Vulvovaginal Atrophy (VVA)

Conditions
-----------------
Vulvovaginal Atrophy

Intervention / Treatment
-----------------
* Drug: WO533


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Post-menopausal women with subjective symptomatology of vulvovaginal atrophy Signed written informed consent before participation in the trial Exclusion Criteria: Known hypersensitivity against any of the ingredients of the investigational product Systemic hormonal replacement therapy, or phytohormonal therapy or use of SERMs within 3 months before and / or during the conduct of the trial Local hormonal therapy (vagina/vulva) within 3 months before the trial If in the opinion of the investigator the patient should not participate in the study for any reason

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: WO533<br>Formulation containing WO533 for intravaginal application | Drug: WO533<br>* Intravaginal application<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| VMI | Change of the Vaginal Maturation Index (VMI) | Day 1 to 43 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Vaginal pH | Change of vaginal pH | Day 1 to 8, day 8 to 43, and day 1 to 43 | 
| Subjective vulvovaginal atrophy symptoms | Change of severity scoring for each of the subjective symptoms (dryness, itching, burning and pain unrelated to sexual intercourse) and as sum score | Day 1 to 8, day 8 to 43, and day 1 to 43 | 
| Global judgment of the tolerability by the Investigator | Scoring on a scale from 1 to 4 | Day 1 to 43 | 
| Global judgment of the tolerability by the patient | Scoring on a scale from 1 to 4 | Day 1 to 43 | 
| Adverse events |  | Day 1 to 43 |
Erythropoietin for Anemia Due to Zidovudine in Human Immunodeficiency Virus Infection

Study Overview
=================
Brief Summary
-----------------
To determine whether administration of human recombinant erythropoietin (REPO) improved or eliminated the anemia seen in human immunodeficiency virus (HIV) infected patients after therapy with zidovudine (ZDV).

Detailed Description
-----------------
BACKGROUND: Reports had shown that between 24 and 78 percent of patients with Acquired Immune Deficiency Syndrome treated with zidovudine for four to six months developed significant bone marrow toxicity, requiring zidovudine dosage alterations, blood transfusions, or cessation of therapy. While zidovudine efficacy had been demonstrated in patients with AIDS or ARC, it was also evaluated in patients with AIDS-related illness, as well as in asymptomatic HIV-infected individuals. The clinically significant zidovudine-induced anemia developing in a substantial number of these patient groups and requiring blood transfusions could cause a significant drain on the blood supply in the United States. The project was part of an Institute-initiated study on the Pathobiology of Bone Marrow Suppression in AIDS or AIDS-Related Complex. The concept was approved at the May 1987 National Heart, Lung, and Blood Advisory Council. The Request for Applications was released in December 1987. DESIGN NARRATIVE: Double-blind, placebo-controlled. Patients received intravenous REPO (1000 IU/kg) or placebo twice per week. The five patients in Group A had no transfusion history. The five patients in Group B had a history of transfusions. Prior to the study, the authors determined that treatment would continue for twelve weeks or until the hemoglobin reached 12.5 g/dl. After the twelve week study period, patients were eligible to receive open label erythropoietin (500 IU/kg, twice a week). For numerous reasons, recruitment of patients was a major problem in this trial. The study originally estimated a total of 64 patients.

Conditions
-----------------
Acquired Immunodeficiency Syndrome, Anemia, Hematologic Diseases, HIV Infections, Blood Disease

Intervention / Treatment
-----------------
* Procedure: erythropoietin, recombinant


Participation Criteria
=================
Eligibility Criteria
-----------------
No eligibility criteria

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: erythropoietin, recombinant|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Mechanisms and Factors Responsible for the Inhibition of Transposons During Fetal Gonad Development in Humans

Study Overview
=================
Brief Summary
-----------------
This is a single-centre study over 36 months for the inclusion of 30 patients. The selection and inclusion of patients will take place according to the criterion of Medical Termination of Pregnancy at 4 different gestational ages (8-12 weeks of gestation (WG)), 13-16 WG, 17-23 WG and 25-35 WG. The tissue analysed will principally be the gonads, other somatic tissue will also be systematically harvested in parallel (liver and psoas muscle) for control purposes. The gonads will be subjected to molecular biology analyses destined to quantify the expression of transposons and their inhibitors.

Official Title
-----------------
Mechanisms and Factors Responsible for the Inhibition of Transposons During Fetal Gonad Development in Humans

Conditions
-----------------
Medical Termination of Pregnancy, Voluntary Termination of Pregnancy

Intervention / Treatment
-----------------
* Other: surgical biopsies


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Couple or mother who has provided written informed consent Foetus between 10 and 37 weeks of amenorrhea (WA) Male foetus Foetus obtained following medical termination of pregnancy or voluntary termination of pregnancy Exclusion Criteria: persons without national health insurance cover foetus presenting aneuploidy foetus presenting a malformation of the genital organs

Ages Eligible for Study
-----------------
Minimum Age: 10 Weeks
Maximum Age: 37 Weeks

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Foetus<br> | Other: surgical biopsies<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Spatio-temporal analysis of the activity of TEs by RT-qPCR and immunostaining |  | Baselines | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Promoter methylation profile by pyrosequencing |  | Baselines | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Male foetuses of 10 to 37 weeks
Vascular Endothelial Growth Factor (VEGF) & LOC387715/HTRA1 Polymorphism in Polypoidal Choroidal Vasculopathy

Study Overview
=================
Brief Summary
-----------------
This study is to investigate whether there is an association of the LOC387715/HTRA1 and vascular endothelial growth factor polymorphism with response to treatment with intravitreal ranibizumab injections for patients with polypoidal choroidal vasculopathy.

Detailed Description
-----------------
This is a retrospective comparative case series comprised of 70 patients being treated for polypoidal choroidal vasculopathy with intravitreal ranibizumab injections and 112 control subjects. Patients were genotyped for the LOC387715 (rs10490924), HTRA1 gene (rs11200638), and VEGF (rs3025039 and rs833069)polymorphism using Real-Time polymerase chain reaction.

Official Title
-----------------
Association of Vascular Endothelial Growth Factor and LOC387715/HTRA1 Polymorphisms With the Response to Intravitreal Ranibizumab Injections in Polypoidal Choroidal Vasculopathy

Conditions
-----------------
Age-Related Macular Degeneration

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients older than 60 years of age at onset polyp-like terminal aneurysmal dilations with or without branching vascular networks in ICGA and subretinal reddish-orange protrusions corresponding to polyp-like lesions patients who had intravitreal injections of 0.5 mg of ranibizumab monthly for 3 months Exclusion Criteria: patients with retinal or choroidal diseases including pathologic myopia, angioid streaks, idiopathic choroidal neovascularization (CNV), presumed ocular histoplasmosis, and other secondary CNV patients who refused genotypic analyses

Ages Eligible for Study
-----------------
Minimum Age: 60 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| polypoidal choroidal vasculopathy<br>patients who were treated for polypoidal choroidal vasculopathy with intravitreal injections of 0.5 mg of ranibizumab monthly for 3 months | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Best-corrected visual acuity | Best-corrected visual acuity (BCVA) using the Snellen chart was evaluated including BCVA before treatment and BCVA up to 12 months. | up to 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Angiographic characteristics | Fluorescein angiography (FA) and ICGA (HRA; Heidelberg Engineering, Dossenheim, Germany)were evaluated. Greatest linear dimension (GLD) was determined based on both FA and ICGA. | up to 12 months |
The Role of the Seven Sweeps in the Prevention of the Prostate Cancer Among Those With a Positive Family History

Study Overview
=================
Brief Summary
-----------------
The seven sweeps is a recommended act performed by men after urinating in order to be confident that no urine is left in the urethra, and its not compulsory to perform. It is performed by the following way: after urinating, the anus is first purified if it has become impure; then, the middle finger of the left hand is slid three times from the anus up to the scrotum; then, the thumb is placed on the penis and the forefinger is placed under the penis, and the thumb and forefinger are pulled three times along the penis up to the point of circumcision; finally, the end of the penis is pressed three times.

Detailed Description
-----------------
The investigators have investigated 350 people who have been doing this habit for at least 20 years of their life and they have a family history of prostatic cancer to check the effect of this procedure on the prevention of the cancer. The investigators have excluded 135 participants of them because they have not full-filled the criteria of inclusion. So 215 of them have been included and investigated using PSA and prostate ultrasound.

Official Title
-----------------
The Role of the Seven Sweeps in the Prevention of the Prostate Cancer Among Those With a Positive Family History: A Retrospective Cohort Study

Conditions
-----------------
Prostatic Hyperplasia, Prostate Cancer, Prostatic Neoplasms

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Family history of prostate cancer, more than 40 years of age, is doing the seven sweeps habit for at least 20 years, has not any urinary problems or chronic diseases. Exclusion Criteria: No family history of prostate cancer, less than 40 years of age of more than 70 years old, has a urinary problem or chronic diseases.

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
Male

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prostate specific antigen | PSA is a protein made by the prostate gland. The amount of PSA may be higher in men who have prostate cancer, benign prostatic hyperplasia (BPH), or infection or inflammation of the prostate. Also called prostate-specific antigen test. | 30 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prostate ultrasound | Using the sonography to locate and measure the thickness and the tissue of the prostate. | 30 minutes | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Prostate cancer, Prostate hyperplasia, The seven sweeps
Enoxaparin as Treatment for Vulvodynia

Study Overview
=================
Brief Summary
-----------------
The investigators hypothesize that injections of Low molecular weight heparin (LMWH) [enoxaparin] will reduce pain in women with vulvodynia.

Official Title
-----------------
Enoxaparin as Treatment for Vulvar Vestibulitis Syndrome - Vulvodynia

Conditions
-----------------
Vulvodynia

Intervention / Treatment
-----------------
* Drug: Clexane (enoxaparin)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: women with vulvodynia Exclusion Criteria: women without vulvodynia

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br> | Drug: Clexane (enoxaparin)<br>* One arm receives enoxoparin, second arm receives saline<br>|
| Placebo Comparator: 2<br> | Drug: Clexane (enoxaparin)<br>* One arm receives enoxoparin, second arm receives saline<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| vestibular pain |  | one year |
Dislocated Stable Distal Both-Bone Forearm Fractures in Children

Study Overview
=================
Brief Summary
-----------------
We create a randomized clinical trial between treatment with and without Kirschner wire fixation of a stable dislocated distal both-bone forearm fracture.

Detailed Description
-----------------
children who arrive at the emergency unit with a dislocated both-bone distal forearm fracture will be asked to join the trial. After informed consent, a randomization between 2 kinds of treatment will be done: K-wire fixation or no K-wire fixation of the fracture after a stable reposition. Outpatient clinic visits till a follow-up of 6 months. During these visits we will investigate: the number of re-dislocations, re-operations, consolidation and dislocation on X-ray, function of both arms, complains in daily living and complications.

Official Title
-----------------
Treatment of Stable Dislocated Both-Bone Distal Forearm Fractures in Children: A Randomized Trial Between Treatment With en Without Kirschner-Wires

Conditions
-----------------
Fracture, Forearm, Distal, Child, Treatment

Intervention / Treatment
-----------------
* Procedure: Kirschner-wires or not


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: both-bone forearm fracture distal dislocated stable after reposition age < 16 years Exclusion Criteria: fracture older than 1 week no informed consent refracture open fracture (Gustillo 2 and 3) both fractures of type torus

Ages Eligible for Study
-----------------
Maximum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Kirschner-wires or not|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| re-operations/ re-dislocations |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pronation and supination |  |  | 
| complications, function, esthetics, complains in daily living, X-rays |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Fracture, Forearm, Distal, Child, Treatment
Gabapentin - A Solution to Uremic Pruritus?

Study Overview
=================
Brief Summary
-----------------
To investigate using the drug gabapentin to relieve the intense pruritic sensation associated with chronic renal failure patients undergoing peritoneal dialysis.

Official Title
-----------------
Gabapentin - A Solution to Uremic Pruritus? A Prospective, Randomized, Placebo-controlled, Double-blind Study

Conditions
-----------------
Pruritus, Uremia

Intervention / Treatment
-----------------
* Drug: Gabapentin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult Chinese male and female patients aged > 18 undergoing CAPD for at least 3 months and able to read and understand Chinese Patients experiencing moderate to severe pruritis, defined as persistent, treatment-resistant pruritis considerably impairing sleep or daytime activity. Treatment resistance is defined as no or only partial resolvement of pruritis under current anti-pruritis treatment regimens such as anti-pruritis lotions and anti-histamines. Patients in stable clinical condition in terms of peritoneal dialysis and general health Patients able to understand and answer the SDS questionnaire Patients able to express the sensation of itchiness in the terms of the VAS and the SDS score Patients who are willing to give written informed consent and to participate in and comply with the study protocol Exclusion Criteria: Patients with a known history of pruritis or dermatologic disease antedating renal failure. Patients with skin disease other than the usual cutaneous findings of uraemia such as xerosis or ecchymosis. Patients under current treatment with systemic steroids Known history of allergy to Gabapentin Those patients already put on anti-convulsants Unable to give written informed consent for the study Pregnancy or female patients of child-bearing age who are unwilling to use contraception Poor drug compliance Known HIV positivity Active neoplastic disease Those who do not want to participate the study
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Gabapentin|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Subjective measurement of reduction in pruritus |  | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Tolerability of Gabapentin in CAPD patients |  | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Uremic pruritis